Warfarin 500microgram tablets

البلد: المملكة المتحدة

اللغة: الإنجليزية

المصدر: MHRA (Medicines & Healthcare Products Regulatory Agency)

العنصر النشط:

Warfarin sodium

متاح من:

Sun Pharma UK Ltd

ATC رمز:

B01AA03

INN (الاسم الدولي):

Warfarin sodium

جرعة:

500microgram

الشكل الصيدلاني:

Oral tablet

طريقة التعاطي:

Oral

الفئة:

No Controlled Drug Status

نوع الوصفة الطبية :

Valid as a prescribable product

ملخص المنتج:

BNF: 02080200; GTIN: 5060011720316

نشرة المعلومات

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
WARFARIN
0.5, 1, 3 AND 5 MG TABLETS
(Warfarin Sodium)
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may
harm them, even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Warfarin Tablets are and what they are used for
2.
What you need to know before you take Warfarin Tablets
3.
How to take Warfarin Tablets
4.
Possible side effects
5.
How to store Warfarin Tablets
6.
Contents of the pack and other information
1.
WHAT WARFARIN TABLETS ARE AND WHAT THEY ARE USED FOR
Warfarin Tablets belong to a group of drugs called anti-coagulants.
You take Warfarin
Tablets to help thin your blood if you have had a heart problem,
problems with blood clots or
your blood flow. You may also be given Warfarin Tablets if you have
been fitted with a
replacement heart valve.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE WARFARIN TABLETS
DO NOT TAKE WARFARIN TABLETS IF YOU:
-
are allergic to warfarin sodium or any of the other ingredients of
this medicine (listed in
section 6)
-
are pregnant, breast-feeding or planning to become pregnant
-
have problems with your liver or kidneys
-
have had an infection of the lining of your heart
-
have a condition which causes bleeding (such as a peptic ulcer) or
makes you bruise
easily
-
have high blood pressure
-
are taking the herbal remedy, St John’s Wort (Hypericum perforatum)
for depression
Do not take Warfarin Tablets within 24 hours of surgery or giving
birth to a child.
TALK TO YOUR DOCTOR IF YOU:
-
plan to have any surgery or a dental procedure. Tell all of your
healthcare professionals
and dentists that y

خصائص المنتج

OBJECT 1
WARFARIN 0.5MG TABLETS
Summary of Product Characteristics Updated 24-May-2017 | Ranbaxy (UK)
Limited a Sun
Pharmaceutical Company
1. Name of the medicinal product
Warfarin 0.5 mg Tablets
2. Qualitative and quantitative composition
Each tablet contains Warfarin Sodium 0.5 mg.
Excipient with known effect: 98.25 mg lactose anhydrous per tablet.
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Tablet
Warfarin 0.5 mg Tablets are white, flat round tablets, with a 7.0 mm
diameter, plain on one side and
scored on the other, engraved with “W” above the score and
“0.5” underneath.
The tablet can be divided into equal halves.
4. Clinical particulars
4.1 Therapeutic indications
Warfarin is indicated for the prophylaxis of systemic embolisation in
patients with rheumatic heart
disease and atrial fibrillation.
Warfarin is indicated for the prophylaxis after insertion of
prosthetic heart valves.
Warfarin is indicated for the prophylaxis and treatment of venous
thrombosis and pulmonary embolism.
Warfarin is indicated for transient cerebral ischaemic attacks.
4.2 Posology and method of administration
Posology
_Adults and elderly patients: _The typical induction dose of warfarin
is 10 mg daily for 2 days, but this
should be tailored to individual requirements. Baseline prothrombin
measurements (PT) should be taken
before beginning therapy with warfarin.
The daily maintenance dose of warfarin is usually 3 to 9 mg taken at
the same time each day. The exact
maintenance dose for an individual is dependent on the prothrombin
time or other appropriate coagulation
tests.
The maintenance dose is omitted if the prothrombin time is excessively
prolonged. Once the maintenance
dose is stabilised in the therapeutic range, it is rarely necessary to
alter it.
In emergencies, anticoagulant therapy should be initiated with heparin
and warfarin together. Where there
is less urgency, as in patients disposed to or at special risk of
thromboembolism, anticoagulant therapy
may be initiated with warfarin alone.
C